is allulose a glp-1 agonist GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome Allulose and GLP-1: Potential Benefits

Description

Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide

The Y138 1.36b A mutation in GCGR greatly decreased the potency of retatrutide-induced cAMP signaling by 26.9-fold, while Y138 1.36b L moderately increased it, suggesting the hydrophobic interactions at 1.36b play a crucial role (Fig

2 Kidney Disease Risk Reduction In addition, the FDA has approved semaglutide (Ozempic) to slow the progression of kidney disease and reduce the risk of kidney failure, making it the most widely indicated GLP-1 drug